4D Molecular Therapeutics, Inc. (FDMT) Free cash flow 2019–2025
4D Molecular Therapeutics, Inc. (FDMT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$109.6MFY2025 · since FY2019: -$39.9M → -$109.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$109.6M | +20.8% |
| FY2024 | -$138.4M | -76.1% |
| FY2023 | -$78.6M | +20.0% |
| FY2022 | -$98.2M | -25.5% |
| FY2021 | -$78.2M | -50.7% |
| FY2020 | -$51.9M | -30.1% |
| FY2019 | -$39.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More FDMT financial trends
FDMT RevenueFDMT Net incomeFDMT Net marginFDMT Gross profitFDMT Gross marginFDMT Operating incomeFDMT Operating marginFDMT Operating cash flowFDMT Capital expendituresFDMT Return on equityFDMT Stock buybacksFDMT Dividends paidFDMT Total assetsFDMT Total liabilitiesFDMT Shareholders’ equityFDMT overview →